ライフサイエンスコーパス: trichiasis

1 nal study was performed in 190 subjects with trichiasis.

2 the programmatic management of trachomatous trichiasis.

3 Worldwide, there are 8 million people with trichiasis.

4 f eyelid contour abnormalities and recurrent trichiasis.

5 f adaptive immune responses at this stage of trichiasis.

6 I, 1.74-15.05; P=0.001) were associated with trichiasis.

7 ormally compared for the management of minor trichiasis.

8 nor trichiasis (1-4 lashes), and 42 (17%) no trichiasis.

9 23%), becoming more frequent with increasing trichiasis.

10 major trichiasis (5+ lashes), 75 (31%) minor trichiasis (1-4 lashes), and 42 (17%) no trichiasis.

11 ses), persistent canthal dystopia (3 cases), trichiasis (2 cases), pyogenic granuloma (2 cases), eyel

12 At baseline 124 (52%) eyes had major trichiasis (5+ lashes), 75 (31%) minor trichiasis (1-4 l

13 rly four times more likely to have recurrent trichiasis (95% confidence interval, 1.7-9.3).

14 teria were age less than 18 years, recurrent trichiasis after previous surgery, hypertension, and pre

15 Of the eyelids treated, 2.3% had recurrent trichiasis and 1.3% had an eyelid closure defect.

16 At 4 years, 30% of patients had bilateral trichiasis and 21% had bilateral corneal opacity.

17 When antisera from 33 trichiasis and 26 control patients (with relatively high

18 Surgery is offered to individuals with trichiasis and antibiotic mass drug administration and i

19 eyelashes) or inflammatory trachoma without trichiasis and control subjects without disease, all of

20 on (29%) and was associated with progressive trichiasis and corneal opacification.

21 Trichiasis and distichiasis changed in neither group (P

22 as conducted to investigate attitudes toward trichiasis and its treatment and to determine the rate o

23 Outcome measures included attitudes toward trichiasis and its treatment, reported barriers to surgi

24 on and entropion in 8% (2/25; P = 0.47), and trichiasis and metaplastic lashes in 24% (6/25; P = 0.03

25 Baseline major trichiasis and mixed location lashes and immediate posto

26 ize the reported incidence of post-operative trichiasis and other poor outcomes of trichiasis surgery

27 icipants, 101 (68.2%) were confirmed to have trichiasis, and 118 (80%) had conjunctival swabs positiv

28 cases with trachomatous scarring but without trichiasis, and 360 controls without scarring.

29 omatis infection causes scarring, entropion, trichiasis, and blinding corneal opacification.

30 BLTR surgery for management of trachomatous trichiasis, and could be the preferred procedure for the

31 aron, ankyloblepharon, ectropion, entropion, trichiasis, and metaplastic lashes also were analyzed.

32 SAFE; namely, surgery to treat trachomatous trichiasis, antibiotic mass drug administration to treat

33 ion developed the SAFE strategy (Surgery for trichiasis; Antibiotics for Chlamydia trachomatis infect

34 and CT706 collectively reacting with 30% of trichiasis antisera but none from the normal group, and

35 CT442 reacted with 35% of normal and 19% of trichiasis antisera respectively.

36 that had major (10%) compared to minor (5%) trichiasis at baseline.

37 val [CI] 16.5%-30.6%) of subjects with major trichiasis attended for surgery during the year.

38 roup, and antigen CT695 reacting with 61% of trichiasis but only 31% of normal antisera.

39 Cumulative recurrent trichiasis by 12 months was more frequent in the BLTR gr

40 rtion of individuals who developed recurrent trichiasis by 12 months.

41 Recruited for the study were 121 trichiasis case-control pairs and 117 conjunctival scarr

42 non-communicable, cicatricial and, owing to trichiasis, eventually blinding disease that supervenes

43 t of patients who had undergone surgery were trichiasis free at last follow-up.

44 ith 46% of normal antisera and none from the trichiasis group, whereas antigen CT442 reacted with 35%

45 tigens were preferentially recognized by the trichiasis group, with antigens CT414, CT667, and CT706

46 severe conjunctival inflammation and severe trichiasis (>10 lashes) at baseline.

47 By 4 years, trichiasis had developed in 12 (29%) of 42 previously un

48 of compliance with surgery for trachomatous trichiasis has become a priority of the World Health Org

49 health programme, which promotes surgery for trichiasis (ie, the S component), antibiotics to clear t

50 ntional studies that measured post-operative trichiasis in Africa as an outcome of trichiasis surgery

51 A cohort of Gambians with trichiasis in one or both eyes who had declined surgery

52 Three hundred ninety-four persons with trichiasis in Tanzania were examined.

53 The reported incidence of post-operative trichiasis in the included studies ranged from 2% (at 6

54 st that HLA-DRB*11 may offer protection from trichiasis in trachoma hyperendemic villages.

55 conjunctival tissue remodeling and recurrent trichiasis in trachoma.

56 otentially in-turned eyelashes (trachomatous trichiasis) in later life.

57 munities with or without end-stage trachoma (trichiasis) in The Gambia.

58 Persons with major trichiasis (involving five lashes or more) were referred

59 Trichiasis is associated with increased risk of bacteria

60 However, the prevalence of trachomatous trichiasis is below the threshold for elimination as a p

61 However, recurrent trichiasis is frequent.

62 Surgery for trichiasis is one of the pillars of the World Health Org

63 fication develops infrequently, unless major trichiasis is present.

64 implementing the SAFE Strategy: surgery for trichiasis, mass distribution of antibiotics, promotion

65 However, disease progression to trichiasis occurs even in regions where chlamydial preva

66 l bacteria was independently associated with trichiasis (odds ratio [OR] 6.93; 95% confidence interva

67 case-control study design, individuals with trichiasis or conjunctival scarring (without trichiasis)

68 dertaken to investigate whether trachomatous trichiasis or conjunctival scarring are associated with

69 and potentially blinding inturned eyelashes (trichiasis or entropion) in later life.

70 A high incidence of post-operative trichiasis or other poor surgical outcomes could jeopard

71 Longitudinal studies of trichiasis patients after surgery are needed.

72 Trichiasis patients presenting for surgery were evaluate

73 When 61 trichiasis patients were compared with their control cou

74 Trichiasis progressed in the long-term in this environme

75 Minor trichiasis progressed to major in 28 (37%) of 75 eyes.

76 Trichiasis recurrence and active trachoma at study visit

77 conducted to evaluate risk factors for early trichiasis recurrence and other unfavorable short-term o

78 Trichiasis recurrence rates were high, and most cases re

79 Several studies of trichiasis recurrence suggest an association between sur

80 and evaluated for eyelid closure defect and trichiasis recurrence; in addition, in two thirds of the

81 Baseline trichiasis severity was predictive of eyelid contour abn

82 ial infection was more common with increased trichiasis severity.

83 swab scrapes were taken from subjects in the Trichiasis Study Group (TSG), which studied females only

84 egulated gene in the conjunctival samples of trichiasis subjects.

85 Although trichiasis surgery can reduce the risk of blindness, ret

86 rative trichiasis and other poor outcomes of trichiasis surgery in Africa.

87 Recurrence after trichiasis surgery is high, suggesting that vigilant fol

88 The World Health Organization recommends trichiasis surgery to prevent blindness caused by tracho

89 First-time trichiasis surgery was performed on 2615 eyelids.

90 rative trichiasis in Africa as an outcome of trichiasis surgery were included.

91 hts the need for follow-up of patients after trichiasis surgery.

92 Trichiasis surgical outcomes should be improved.

93 ividual's lifetime are needed to precipitate trichiasis; thus, opportunity exists for a just global h

94 data on the natural history of trachomatous trichiasis to guide program planning or that investigate

95 elid surgery is done to correct trachomatous trichiasis to prevent blindness.

96 or follicular trachoma (TF) and trachomatous trichiasis (TT) 2 years after mass drug administration (

97 limination is the management of Trachomatous Trichiasis (TT) after Trachoma inflammation-follicular (

98 ction from or susceptibility to trachomatous trichiasis (TT) have been identified through genetic ass

99 Unfavorable outcomes after trachomatous trichiasis (TT) surgery are undermining the global trach

100 rring is an underlying cause of trachomatous trichiasis (TT) that can lead to blindness.

101 Patients with trachomatous trichiasis (TT) were randomized to surgery with standard

102 Eight million people have trachomatous trichiasis (TT).

103 obtained from individuals with trachomatous trichiasis (TT; one or more inturned eyelashes) or infla

104 Recurrent trichiasis was associated with a reduced MMP-1 to TIMP-1

105 One year after surgery, recurrent trichiasis was associated with a reduced MMP-1/TIMP-1 ra

106 -year prospective investigation of recurrent trichiasis was conducted in The Gambia.

107 e referred for surgery, and those with minor trichiasis were advised to epilate.

108 Patients with trichiasis were examined at baseline, 6 months, 1 year,

109 Eyes with trichiasis were more frequently infected with bacteria (

110 older with signs or symptoms consistent with trichiasis were recruited and conjunctival swabbing for

111 1000 participants with trichiasis were recruited, randomly assigned, and treate

112 hundred forty individuals with trachomatous trichiasis were recruited.

113 trichiasis or conjunctival scarring (without trichiasis) were compared with normal matched control su

114 2) was significantly associated with lack of trichiasis, whereas HLA-B*07 (OR, 3.26; 95% CI, 1.42-7.4

115 Blindness follows the development of trichiasis, which is treated surgically.

116 Participants had upper lid trachomatous trichiasis with one or more eyelashes touching the eye o

117 rofiles between Ethiopians with trachomatous trichiasis (with [TTI] or without [TT] inflammation) and